Lead Product(s) : Epeleuton
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRIAGE is a dose finding Phase IIb study being conducted in Germany, Israel, Latvia, Switzerland and the United States to assess the efficacy and safety of orally administered epeleuton in 240 patients with hypertriglyceridemia and type 2 diabetes.
Product Name : DS102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Epeleuton
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable